DDO-6600

DDO-6600 is a covalent Hsp90 inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, c-Raf) . DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer[1].

Product Specifications

CAS Number

[2640292-37-9]

UNSPSC

12352005

Target

Akt; Apoptosis; CDK; HSP; Raf

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

O=C(N1C(CCCC1)C(N)=O)/C=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC(C)=C(C=C4)C

Molecular Formula

C26H28N4O2

Molecular Weight

428.53

References & Citations

[1]Li L, et al. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. Cell Chem Biol. 2021 Oct 21;28 (10) :1446-1459.e6.